Structure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor Design

被引:55
|
作者
Meng, Fei [2 ]
Hou, Jing [1 ]
Shao, Yong-Xian [1 ]
Wu, Pei-Ying [3 ,4 ]
Huang, Manna [2 ]
Zhu, Xinhai [2 ]
Cai, Yonghong [1 ]
Li, Zhe [1 ]
Xu, Jie [1 ]
Liu, Peiqing [1 ]
Luo, Hai-Bin [1 ]
Wan, Yiqian [2 ]
Ke, Hengming [1 ,3 ,4 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sch Chem & Chem Engn, Guangzhou 510275, Guangdong, Peoples R China
[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA
关键词
9; PDE9; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURES; DRUG DEVELOPMENT; CGMP; POTENT; AGENTS; CAMP; PF-04447943; INSIGHT;
D O I
10.1021/jm301189c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A new series of phosphodiesterase-9 (PDE9) inhibitors that contain a scaffold of 6-amino-pyrazolopyrimidinone have been discovered by a combination of structure-based design and computational docking. This procedure significantly saved the load of chemical synthesis and is an effective method for the discovery of inhibitors. The best compound 28 has an IC50 of 21 nM and 3.3 mu M, respectively, for PDE9 and PDE5 and about 3 orders of magnitude of selectivity against other PDE families. The crystal structure of the PDE9 catalytic domain in complex with 28 has been determined and shows a hydrogen bond between 28 and Tyr424. This hydrogen bond may account for the 860-fold selectivity of 28 against PDE1B, in comparison with about 30-fold selectivity of BAY73-6691. Thus, our studies suggest that Tyr424, a unique residue of PDE8 and PDE9, is a potential target for improvement of selectivity of PDE9 inhibitors.
引用
收藏
页码:8549 / 8558
页数:10
相关论文
共 50 条
  • [1] Insight into Binding of Phosphodiesterase-9A Selective Inhibitors by Crystal Structures and Mutagenesis
    Wang, Huanchen
    Luo, Xuan
    Ye, Mengchun
    Hou, Jing
    Robinson, Howard
    Ke, Hengming
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (04) : 1726 - 1731
  • [3] Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds
    Li, Zhe
    Lu, Xiao
    Feng, Ling-Jun
    Gu, Ying
    Li, Xingshu
    Wu, Yinuo
    Luo, Hai-Bin
    MOLECULAR BIOSYSTEMS, 2015, 11 (01) : 115 - 125
  • [4] Structure-based design and discovery of potent and selective KDM5 inhibitors
    Nie, Zhe
    Shi, Lihong
    Lai, Chon
    O'Connell, Shawn M.
    Xu, Jiangchun
    Stansfield, Ryan K.
    Hosfield, David J.
    Veal, James M.
    Stafford, Jeffrey A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (09) : 1490 - 1494
  • [5] Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain
    Denny, R. Aldrin
    Flick, Andrew C.
    Coe, Jotham
    Langille, Jonathan
    Basak, Arindrajit
    Liu, Shenping
    Stock, Ingrid
    Sahasrabudhe, Parag
    Bonin, Paul
    Hay, Duncan A.
    Brennan, Paul E.
    Pletcher, Mathew
    Jones, Lyn H.
    Chekler, Eugene L. Piatnitski
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (13) : 5349 - 5363
  • [6] Structure-based design of selective phosphodiesterase 4B inhibitors based on ginger phenolic compounds
    Xing, Ming
    Akowuah, Gabriel Akyirem
    Gautam, Vertika
    Gaurav, Anand
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2017, 35 (13): : 2910 - 2924
  • [7] Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor
    Martin, Laetitia J.
    Koegl, Manfred
    Bader, Gerd
    Cockcroft, Xiao-Ling
    Fedorov, Oleg
    Fiegen, Dennis
    Gerstberger, Thomas
    Hofmann, Marco H.
    Hohmann, Anja F.
    Kessler, Dirk
    Knapp, Stefan
    Knesl, Petr
    Kornigg, Stefan
    Muller, Susanne
    Nar, Herbert
    Rogers, Catherine
    Rumpel, Klaus
    Schaaf, Otmar
    Steurer, Steffen
    Tallan, Cynthia
    Vakoc, Christopher R.
    Zeeb, Markus
    Zoephel, Andreas
    Pearson, Mark
    Boehmelt, Guido
    McConnell, Darryl
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (10) : 4462 - 4475
  • [8] Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening
    Dighe, Satish N.
    Deora, Girdhar Singh
    De la Mora, Eugenio
    Nachon, Florian
    Chan, Stephen
    Parat, Marie-Odile
    Brazzolotto, Xavier
    Ross, Benjamin P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (16) : 7683 - 7689
  • [9] Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design
    Fujimori, Ikuo
    Wakabayashi, Takeshi
    Murakami, Morio
    Okabe, Atsutoshi
    Ishii, Tsuyoshi
    McGrath, Aaron
    Zou, Hua
    Saikatendu, Kumar Singh
    Imoto, Hiroshi
    ACS OMEGA, 2020, 5 (49): : 31984 - 32001
  • [10] Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor
    Huang, Manna
    Shao, Yongxian
    Hou, Jianying
    Cui, Wenjun
    Liang, Beibei
    Huang, Yingchun
    Li, Zhe
    Wu, Yinuo
    Zhu, Xinhai
    Liu, Peiqing
    Wan, Yiqian
    Ke, Hengming
    Luo, Hai-Bin
    MOLECULAR PHARMACOLOGY, 2015, 88 (05) : 836 - 845